In this episode, Dr. Valentin Fuster summarizes the March 25, 2025, issue of the JACC, which focuses on advancements in electrophysiology. Highlights include groundbreaking studies on leadless pacemakers, atrial fibrillation treatments, and appropriate use criteria for cardiac devices, with key papers exploring the safety of pacemaker retrieval, the role of electrograms in ablation procedures, and long-term outcomes for left atrial appendage occlusion devices.

In this video on research published in JACC and presented at ACC.25, Yuan Lu, ScD, JACC: Executive Associate Editor, discusses her study on optimal blood pressure management for adults aged 80 and above. Her study found that systolic blood pressure below 130 mmHg is associated with lower cardiovascular risk, while levels above 145 mmHg increase heart-related mortality. The study supports intensive blood pressure management but emphasizes the need for personalized treatment and further research on long-term effects and potential risks.#jacc #jaccjournals #acc25

In this video discussion with JACC: Associate Editor Michelle M. Kittleson, MD, PhD, FACC, and authors Eric Hall, MD and James A. de Lemos, MD, FACC, they review this study published in JACC & presented at ACC.25. Do patients who survive cardiogenic shock have neurocognitive consequences at intermediate-term follow-up? New cognitive impairment is common at discharge and 3 months after CS and is associated with worse quality of life and functional status. #jacc #jaccjournals #acc25

In this brief report from the BMC2 registry published in JACC and presented at ACC.25, Eric Cantey, MD, FACC, and Celina Yong discuss the study findings. In light of the DanGer Shock Trial, there is a need to define the current practice patterns in the care of AMI-CS. There is overall low annual case volumes of AMI-CS with significant heterogeneity in the intraprocedural utilization of MCS and RHC.

Join JACC: Executive Associate Editor Mitsuaki Sawano, MD, FACC, and author Mats Lassen, MD discuss Dr. Lassen's study on the link between acute respiratory syncytial virus (RSV) infection and an increased incidence of cardiovascular events, particularly in older adults, using comprehensive nationwide data from Denmark. The findings, published in JACC and presented at ACC.25, highlight the need for heightened awareness among healthcare providers, potential adjustments in patient management during RSV season, and further research into whether RSV vaccines may help reduce cardiovascular complications. #jacc #jaccjournals #acc.25

Hosts Mitsuaki Sawano, MD, and Shun Kohsaka, MD, FACC, discuss the end of Skype and before welcoming Dr. Nobuyuki Kagiyama, MD (Juntendo University), to explore findings from the SONIC-HF Registry on the prognostic value of diaphragm ultrasound in heart failure patients. The episode covers ultrasound methodology, research challenges, and clinical implications for heart failure management.

Listen to the editor's page of the March 18th JACC issue, Harlan M. Krumholz, MD, SM, and Kushal T Kadakia, MSc, examine the troubled history of the Select IVC filter, a device approved by the FDA in 2007, which was later linked to severe safety issues due to clinical trial misconduct and regulatory oversights. In this audio version of their page, they note that the case reveals systemic vulnerabilities in medical research, regulation, and publication practices, emphasizing the importance of transparency, rigorous oversight, and ethical conduct in medical device development. They propose key actions for regulators, industry, medical journals, and clinicians to improve patient safety, trust, and the integrity of medical research.

In this episode, Dr. Valentin Fuster highlights key research from the March 18th, 2025 issue of the JACC. The studies cover groundbreaking findings in heart failure management, genetic testing in cardiovascular diseases, the effectiveness of a new drug for amyloidosis, and the cardiovascular harm caused by smoking, offering valuable insights for clinical practice and patient care.

In this episode, Dr. Valentin Fuster discusses a study on sodium zirconium cyclosilicate (SZC) for managing hyperkalemia in heart failure patients on mineralocorticoid receptor antagonists (MRAs) like spironolactone. While SZC effectively reduced hyperkalemia and allowed higher spironolactone doses, concerns over worsening heart failure events highlight the complex balance between treatment benefits and risks.

In this episode, Dr. Valentin Fuster discusses a 14-year study on the clinical impact of genetic testing for inherited cardiovascular diseases, conducted by Dr. Steffany Grondin at the Montreal Heart Institute. The study found that genetic testing helped diagnose 24% of patients, refine clinical management, and improve variant interpretation, while also highlighting the need for more research and better access to genetic expertise in healthcare.